ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
Ainscow Donald George reported acquisition or exercise transactions in this Form 4 filing.
ASP Isotopes Inc. executive vice president and general counsel Donald George Ainscow received an award of 400,000 shares of common stock as compensation. The filing shows he now holds 900,000 common shares directly. The award will vest in semi-annual installments over four years, subject to applicable vesting conditions beginning on the grant date.
ASP Isotopes Inc. reported that Chief Financial Officer Heather Kiessling acquired 840,000 shares of common stock through a stock award with a grant price of $0.0000 per share. Following this award, she holds a total of 1,549,376 common shares directly.
The award will vest in semi-annual installments over a four-year period, subject to applicable vesting conditions, meaning the shares are earned gradually over time rather than all at once.
Independent Trading Group (ITG) Inc. reported a Form 144 notice showing insider selling activity and recent equity compensation. The filing lists a sale of $881,463.71 for 162,153 shares reported on 03/02/2026. It also shows 2,233,555 restricted shares acquired as compensation on 05/28/2026. Shares outstanding are stated as 125,903,447 as of 06/01/2026.
ASP Isotopes Inc. reported operational progress at its Silicon-28 enrichment facility in Pretoria, South Africa. The company has successfully restarted the first 18 stages of the plant after nine months of engineering enhancements to non-core components such as valves, compressors, and piping, and these stages have operated for over three weeks at target enrichment levels.
The company has signed three commercial contracts to supply enriched Silicon-28 to U.S.-based customers and expects initial commercial shipments to begin in Q3 2026. Earlier, it shipped first samples in August 2025, with independent analysis confirming enrichment performance. The release highlights Silicon-28’s potential importance for quantum computing and next-generation semiconductors.
ASP Isotopes Inc. furnished an update under Regulation FD by releasing its latest investor presentation on May 20, 2026. The presentation is available on the company’s website home page.
The company states the presentation is not deemed “filed” under the Exchange Act or Securities Act and will not be incorporated by reference into other SEC filings. It includes safe harbor language indicating that some content consists of forward-looking statements subject to risks described in ASP Isotopes’ most recent Form 10-K and other SEC reports.
ASP Isotopes Inc. (ASPI) reported sharp growth in early-stage revenue but remains deeply loss-making as it scales new businesses. For the quarter ended March 31, 2026, revenue rose to $4.2 million from $1.1 million a year earlier, driven by nuclear medicine doses and initial LNG and helium sales.
The company posted a $26.7 million net loss from continuing operations, widening from $8.5 million, reflecting higher R&D and selling, general and administrative expenses as it builds enrichment and gas projects. After income from discontinued operations, overall net loss was $7.1 million, or $0.06 per share.
ASPI ended the quarter with $207.3 million in cash and cash equivalents and $83.2 million in short‑term investments, and management believes this will fund operations for more than 12 months. The acquisition of Renergen added natural gas properties and created a new helium and LNG segment, while Skyline’s deconsolidation is now reported as discontinued operations.
ASP Isotopes Inc. notified the SEC it cannot timely file its Form 10-Q for the period ended March 31, 2026. The company states the delay stems from obtaining and compiling required information and says it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
The notification was signed by Heather Kiessling, Chief Financial Officer, on May 15, 2026.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy, announced a non-binding Memorandum of Understanding with a European nuclear technology company to explore a long-term collaboration for advanced nuclear fuel supply.
The MOU covers potential supply of high assay low enriched uranium (HALEU) with uranium-235 content greater than 10%. The parties plan technical and economic assessments, with a framework where the partner could provide uranium feedstock to Quantum Leap Energy’s planned conversion and enrichment facilities, and Quantum Leap Energy could enrich and potentially deconvert it for delivery.
The MOU runs through December 31, 2030, and contemplates non-binding estimates of HALEU quantities, with potential deliveries beginning in 2028 and volumes scaling up through 2036, aligned with the partner’s reactor development timeline and fuel needs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has appointed Dr. Peter S. Fiske to QLE’s Strategic Advisory Board. QLE focuses on innovative technologies across the nuclear fuel cycle, including uranium enrichment and lithium isotope separation, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies.
Dr. Fiske previously led the U.S. Department of Energy’s five-year, $110 million National Alliance for Water Innovation hub and has extensive experience in technology commercialization, government partnerships, and advanced materials. The press release also reiterates QLE and ASP Isotopes’ use of forward-looking statements subject to significant technical, regulatory, and funding risks.
ASP Isotopes Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and auditor fees. The amendment does not update financial statements and should be read together with the original filing.
For 2025, CEO Paul Mann received total compensation of about $16.8 million, including salary, cash bonus and significant equity awards. The filing also discloses that non‑affiliate market value was approximately $399.8 million and that 125,903,447 common shares were outstanding as of April 29, 2026.